07666 劑泰科技－Ｐ
METIS TECHBIO-P
METIS TECHBIO-P
| Register Close | 2026/05/08 IPO Closing in 2 Days |
| Listing Date | 2026/05/13 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Metis TechBio Co. is a pioneer in AI-empowered nanomaterial innovation, dedicated to the delivery and application of functional payloads across life forms with the commitment to unlocking a healthier world through AI-driven nanotechnology.
--
The foundation of the Group’s AI-driven nanotechnology is NanoForge, a suite of proprietary and synergistic technologies that include its extensive de novo lipid library, AI foundational models, METiS AI Agent, quantum chemistry and molecular dynamics simulations, and AI-driven high-throughput screening platforms.
--
The Group has developed three specialized solution platforms (i.e., AiTEM, AiLNP and AiRNA platforms) that simulate, predict, and interpret nanoscale interactions, enabling the rational design, optimization, and validation of advanced nanomaterials and their associated payloads.
--
The Group has built the industry’s first, largest and most diverse lipid library, comprising over 10 million structurally diverse lipids that serve as the foundational building blocks for targeted delivery. The Group’s customers primarily comprise top global pharmaceutical companies, innovative biotechnology companies, and medical research institutions.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 201.23M H shares |
| No. of International Offer Shares | 191.17M H shares |
| No. of HK Offer Shares | 10.06M H shares |
| Offer Price | $10.50 |
| Stock Code | 7666 |
| Sponsor(s) | Jefferies Hong Kong Limited, Deutsche Securities Asia Limited, CITIC Securities (Hong Kong) Limited |
| Underwriter(s) | Jefferies Hong Kong Limited, Deutsche Bank AG, Hong Kong Branch, CLSA Limited, CMB International Capital Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | May 05 (Tue) - noon, May 08 (Fri) |
| Price Determination Date | -- |
| Result Announcement Date | On or before May 12 (Tue) |
| Result Announcement Date | On or before May 12 (Tue) |
| Result Announcement Date | On or before May 13 (Wed) |
| Dealings in Shares commence on | May 13, 2026. (Wed) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $10.50 |
| Capitalization | 12.10B |
| NAV / share ($) | $2.9 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 10.5, the net proceeds raised would be HKD 1.98B, of which |
| 50% : Fund research of the core technologies supporting AI infrastructure and AI-driven nanomaterial platforms |
| 20% : Ongoing and planned clinical trials of AI-developed pipeline products |
| 10% : Development of animal health and longevity solutions |
| 10% : Support the construction of AI-driven nanomaterials ecosystem globally |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).